AAP
FDMT icon

Arax Advisory Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Arax Advisory Partners’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.5K Sell
268
-185
-41% -$1.61K ﹤0.01% 3041
2025
Q4 		$3.4K Sell
453
-5,585
-92% -$56.7K ﹤0.01% 3044
2025
Q3 		$52.5K Buy
+6,038
New +$36.1K ﹤0.01% 1814
2025
Q2 		– Sell
-628
Closed -$2.03K – 3098
2025
Q1 		$2.03K Buy
+628
New +$2.96K ﹤0.01% 2067

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Arax Advisory Partners's FDMT Position: Q1 2026 in Review

Arax Advisory Partners reduced its 4D Molecular Therapeutics (FDMT) stake by 41% in Q1 2026, selling an estimated $1.61K and leaving 268 shares worth $2.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3041.

Arax Advisory Partners first reported a position in FDMT in Q1 2025 and has held it in 4 quarters since. The position peaked at $52.5K in Q3 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Arax Advisory Partners held 268 shares of 4D Molecular Therapeutics worth $2.5K as of Q1 2026.
  • Arax Advisory Partners sold 185 4D Molecular Therapeutics shares in Q1 2026, an estimated $1.61K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3041 holding.
  • Arax Advisory Partners first reported a position in 4D Molecular Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Arax Advisory Partners's 4D Molecular Therapeutics position peaked at $52.5K in Q3 2025.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.